DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Mark - 3 — - 2 Mark Cuban - 2 Jeff Bottari - 1 Rebecca Zisser - 1 Tesla - 1 Mark Zuckerberg - 1 iStock - 1
Top related locs:
California China United States Humira U.S Organon Bengaluru
Top related orgs:
Service - 2 Business - 2 Walgreens - 2 CVS Health - 2 CVS - 2 Big Tech - 1 Getty Images - 1 Apple - 1

Search resuls for: "Cuban's pharma"


6 mentions found


☆ Insider Today: Mark Cuban vs. Big Pharma
  + stars: | 2024-08-04 | by ( Dan Defrancesco | ) www.businessinsider.com   time to read: +5 min
But first: Big Tech reporting for duty. AdvertisementEven before Amazon, Apple, Meta, and Microsoft reported earnings, investors' focus was clear. Meta CEO Mark Zuckerberg didn't shy away from his intention to keep plowing money into AI, but investors didn't mind. Softening demand from shoppers for Amazon led to a miss in reported net sales and a weaker-than-expected sales forecast for the third quarter. Also read:Getty Images; Jenny Chang-Rodriguez/BIMark Cuban's pharma missionIn 2022, Mark Cuban launched a low-cost online pharmacy with the goal of cutting drug prices for consumers.
Persons: —, Jeff Bottari, Rebecca Zisser, Tesla, Mark Zuckerberg, iStock, That's, Gen, Zers, Tyler Le, Tetiana Lazunova, Jenny Chang, Rodriguez, Cuban's, Mark Cuban, somebody's, Emily Durham Organizations: Service, Business, Big Tech, Getty Images, Apple, Meta, Microsoft, Apple Intelligence, Amazon, pharma, Cuban's pharma, Cost, Pfizer, Novo Nordisk Locations: China
☆ Walgreens is following Mark Cuban's blueprint as it embarks on a big strategy shift for prescription drugs
  + stars: | 2024-01-05 | by ( ) www.businessinsider.com   time to read: +5 min
Pharmacies are changing how they get paid, and Walgreens wants a piece of the action. It's a departure from the traditional, complicated way drugs are paid for, and proponents say it could make drug pricing more transparent and predictable. It's not a given patients will pay less for drugs at the pharmacy counter under this kind of model. These companies are taking cues from Mark Cuban's Cost Plus Drugs, which is starting to gain traction in the market. The big question is whether Walgreens can compete with CVS and other pharmacies in delivering those extra pharmacy and healthcare services.
Persons: Tim Wentworth, Mark, Wentworth, Borja, Hojas, they're, Caremark, Brian Tanquilut, Tanquilut, CVS, Cigna, Mark Cuban's, It's, Rosalind Brewer Organizations: Walgreens, Business, CVS Health, Getty, CVS, Jefferies, Health Locations: California
☆ How Mark Cuban forced the biggest US pharmacy to upend its business
  + stars: | 2023-12-05 | by ( Rebecca Torrence | ) www.businessinsider.com   time to read: +5 min
The new program includes a set markup for medication costs, a step toward drug pricing transparency. The retailer has been facing pressure from new models like Mark Cuban Cost Plus Drugs. They've been especially focused on pharmacy-benefit managers and the lack of transparency around how much drugs cost. How Mark Cuban changed drug pricingCuban's pharmacy buys drugs directly from manufacturers and sells them to consumers at a 15% markup, plus pharmacy fees. AdvertisementBut the announcement looks to be a step in the right direction for drug pricing transparency.
Persons: —, Mark, Prem Shah, Mark Cuban, GoodRx, PBMs, Kroger, it's Organizations: CVS, Cuban, Plus, Service, Mark Cuban, Federal, US Federal Trade Commission, CVS Health, Kroger, Walgreens, Drug, Wall Street Locations: California
☆ Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira
  + stars: | 2023-07-03 | by ( ) www.reuters.com   time to read: +1 min
July 3 (Reuters) - Coherus BioSciences (CHRS.O) said on Monday it has launched a copycat version of AbbVie's (ABBV.N) Humira in the United States at a discount of more than 85% to the blockbuster arthritis drug. Coherus is the latest to launch a biosimilar to Humira in the U.S. market this month after Boehringer Ingelheim, Sandoz and Organon (OGN.N). Coherus said last month it would sell the biosimilar, branded as Yusimry, at $995 per carton, compared with the current list price of Humira of $6,922 per carton. The company has also partnered with billionaire entrepreneur Mark Cuban's pharmaceutical startup to sell the biosimilar at $569.27 plus dispensing and shipping fees. Usually prices fall, often dramatically, when multiple copycat versions of a widely-used medication enter the market.
Persons: Coherus, Boehringer Ingelheim, Mark, Sriparna Roy, Leroy Leo, Shounak Dasgupta, Arun Koyyur Organizations: Coherus BioSciences, Sandoz, Thomson Locations: United States, Humira, U.S, Organon, Bengaluru
☆ Mark Cuban's pharmaceuticals startup ties up with RxPreferred
  + stars: | 2023-01-11 | by ( ) www.reuters.com   time to read: +1 min
Jan 11 (Reuters) - Billionaire entrepreneur Mark Cuban's pharmaceuticals startup has tied up with pharmacy benefits manager RxPreferred Benefits, the companies said on Wednesday, in a move to offer lower priced drugs through some employer-backed health insurance plans. Mark Cuban Cost Plus Drugs provides generic drugs through direct contracts with manufacturers and charges a standard markup on every drug it sells. Under the partnership, RxPreferred Benefits' customers will have the option to use Mark Cuban Cost Plus Drugs as part of their health insurance plans. Mark Cuban Cost Plus Drugs in December partnered with EmsanaRx, a nonprofit coalition of nearly 40 companies including U.S. retailers Walmart (WMT.N) and Costco (COST.O), that operates a PBM service for employers. PBMs serve as intermediaries between drug manufacturers, health insurance plans and pharmacies to negotiate prescription drug prices.
☆ Mark Cuban’s pharmacy startup is actually making drugs less expensive. It's still working on solving the real problem
  + stars: | 2022-07-28 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +5 min
Imatinib, a leukemia medication with a retail price of more than $2,500, is just $14.40 at Cost Plus Drugs. But experts say that Cost Plus Drugs' impact is limited, at least for now, because it hasn't broken into the market driving those exorbitant prices: brand-name drugs. Instead of negotiating prices through those pharmacy benefit managers, Cost Plus Drugs directly negotiates with manufacturers to get generic drugs at wholesale prices. The trade-off: Cost Plus Drugs doesn't accept insurance claims, since insurers don't typically work with pharmacies that avoid pharmacy benefit managers. That gives drugmakers little-to-no incentive to offer rebates to Cost Plus Drugs, Hernandez notes.
0 next >>
Total: 6